IKT — Inhibikase Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $123.41m
- $30.23m
- 41
- 28
- 22
- 20
Annual cashflow statement for Inhibikase Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -2.85 | -14.8 | -18.1 | -19 | -27.5 |
| Depreciation | |||||
| Non-Cash Items | 2.18 | 2.25 | 0.525 | 0.532 | 8.14 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.465 | -1.76 | 0.171 | 0.235 | 0.205 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -1.13 | -14.3 | -17.4 | -18.1 | -19.1 |
| Capital Expenditures | — | — | -0.243 | -0.014 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -15.8 | 11.7 | -37 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | — | — | -16 | 11.7 | -37 |
| Financing Cash Flow Items | — | -0.078 | 0 | -0.139 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 15.1 | 41.1 | -0.205 | 8.4 | 103 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 13.9 | 26.8 | -33.6 | 1.98 | 47.3 |